Orion Oyj Series A | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
267,700.00
272,400.00
266,600.00
314,600.00
293,000.00
387,300
Depreciation, Depletion & Amortization
38,500.00
37,800.00
40,400.00
40,300.00
41,400.00
40,800
Other Funds
69,100.00
56,800.00
37,200.00
72,800.00
67,000.00
187,100
Funds from Operations
237,100.00
253,400.00
269,800.00
282,100.00
267,400.00
241,000
Changes in Working Capital
21,900.00
43,200.00
14,900.00
33,000.00
39,000.00
10,100
Net Operating Cash Flow
215,200.00
296,600.00
254,900.00
249,100.00
228,400.00
230,900
Capital Expenditures
73,300.00
56,400.00
43,200.00
47,700.00
76,500.00
Sale of Fixed Assets & Businesses
2,000.00
1,500.00
1,000.00
26,600.00
1,600.00
Net Investing Cash Flow
71,300.00
54,900.00
42,200.00
21,100.00
74,900.00
Cash Dividends Paid - Total
183,700.00
176,200.00
183,300.00
183,600.00
218,100.00
Issuance/Reduction of Debt, Net
119,800.00
24,300.00
47,500.00
37,000.00
2,200.00
Net Financing Cash Flow
73,500.00
200,500.00
230,800.00
237,400.00
220,300.00
Net Change in Cash
69,500.00
43,800.00
13,300.00
13,300.00
67,800.00
Free Cash Flow
149,300.00
245,100.00
216,500.00
208,100.00
161,300.00
Change in Capital Stock
9,600.00
-
-
16,800.00
-
Exchange Rate Effect
900.00
2,600.00
4,800.00
3,900.00
1,000.00

About Orion Oyj

View Profile
Address
Orionintie 1A
Espoo UU 02200
Finland
Employees -
Website http://www.orion.fi
Updated 07/08/2019
Orion Oyj engages in the development of pharmaceutical and diagnostic test. It develops, manufactures, and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Its pharmaceutical research and development focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.